Subject Index

Subject Index of the 8th International Symposium on Gastrointestinal Hormones appears in vol. 46, suppl. 1, 1990 Subject Index of the 4th International Conference on Intestinal and Pancreatic Adaptation appears in vol. 46, suppl. 2, 1990

(A) = Abstract
Absorption 35
N-Acetyl cysteine 97
Acid inhibition 97
Acinar cell destruction 129 (A)
tissue damage 137(A)
ultrastructure 144 (A) Acini 125(A)
Acute haemorrhagic pancreatitis 176 (A)
mental stress 178(A)
pancreatitis 124 (A), 130 (A), 133 (A), 140 (A), 147(A), 150(A), 154(A), 156(A)
- etiology 159(A)
- shigellosis 127(A)
Adenocarcinoma(s) 128 (A), 129 (A)
Advanced/irresectable pancreatic cancer 170(A) AIDS 169(A)
- children 179(A) Alcohol injections 128(A) Alkalization 139(A)
Ampulla of Vater, tumors 166 (A) Amylase assay 181 (A)
- secretion 157(A)
Anatomical variations and anomalies 169 (A) Anglo-CT pancreatic necrosis 123 (A) Animal model 126 (A) Anti-mitotic activity 125(A) Antioxidants 180(A) Anti-proliferative activity 125 (A) Antiproteases 157(A) Antral distension 137 (A)
- mucosa explant, effect of Helicobacter pylori 46
ARDS 160(A) Arginine 141 (A) Ascites 185(A) Ascorbic acid 148 (A) Aspiration biopsy 145(A)
Atropin 81
- and bombesin effect on pancreatic enzymes 81
Autoimmune reactions 136 (A)
Azapropazonum 156 (A)
BBS 147(A)
Binding protein 187 (A)
Bismuthate, effect in G cell hyperfunction 65
Bombesin 81, 147(A)
- effect on plasma trypsin 81
CA494 138(A)
Ca2+ Mg-ATPase 131 (A)
Subject Index

Cigarette smoking 27  
- gastric juice prostaglandins 27
Cimetidine 61, 233  
- comparison with pirenzepine 233  
- treatment and vitamin D metabolism 61
Cirrhosis 193
Cl--HCO₃ exchange 124 (A) Clostridium difficile 157 (A) Coeliac disease 72  
- occurrence of lung cavities 72
Cyclosporin A 144 (A), 177 (A) Cystic neoplasms 177 (A)
- tumors 145 (A)
CT scan 145 (A), 167 (A), 183 (A) 1-Cyano-2-hydroxy-buten 156 (A) Cytology 135 (A)
Depletion of pancreatic glutathione 156 (A) Dexamethasone 1
Diet 134 (A)
Digestive contents 205
Dimethadione 19
Dog(s) 141 (A)
Doxycycline 29
Calcine chronic pancreatitis 188 (A)
Calculi 174 (A)
Camostat 180 (A)
Carrier 55
Cavity 72
CCK 138 (A), 139 (A), 144 (A), 146 (A), 147 (A), 148 (A), 151 (A), 161 (A), 164 (A), 165 (A), 175 (A), 178 (A), 184 (A), 220
receptor antagonists 161 (A), 168 (A)
release after gastric distension 220
response 147 (A) CCK-9 162 (A) Celiac disease 132 (A) Cell carcinogenesis 130 (A)
growth 131 (A)
Central neural stimulation 163 (A) Cholecystokinin, see also CCK
- release, feedback-controlled 175 (A)
Cholera 127 (A)
Cholestasis, extra-hepatic 128 (A) Cholinergic blockade 114 Chronic pancreatic lesions 169 (A)
- pancreatitis 135 (A), 149 (A), 152 (A), 180 (A), 188 (A)
244
ductal proton secretion 159 (A) Double-blind multicenter trial 140 (A) cross-over study 158 (A) Drain surgery 135 (A) Duodenal polyps 228 ulcer 233
- healing rate, relapse rate, cimetidine, pirenzepine 233
Edematous pancreatitis 174 (A)
EGF, familial adenomatous polyposis 228
- receptors 176 (A)
Emiocyteosis 187 (A)
Endocrine pancreatic insufficiency 152 (A) tumors, surgical treatment 181 (A) Endoscopic ultrasonography 166 (A)
- accuracy 167 (A) Enterochromaffin-like cells 1 Entero-insular axis 184 (A) Enterostatin 136 (A) Enzyme profiles 181 (A)
- secretion, acinar 144 (A)
Epidemiology 10
ERCP 126 (A), 169 (A), 183 (A)
Estramustine 125 (A)
Estrogen 214
Estromustine 125 (A)
Exocrine pancreatic function 126 (A)
- secretion 81, 171 (A), 220 Experimental models 174 (A) pancreatitis 148 (A)
Familial adenomatous polyposis 228
Fast protein liquid chromatography 148 (A) Fecal immunoactive lipase, diagnostic value 163 (A) Ferritin 35 FFA 176 (A)
α-Fluoromethylhistidine 1 Food intake 136 (A) FOY treatment 130 (A) G cell hyperfunction 65
- treatment with bismuthate 65
Gabexate mesilate 159 (A) Gallbladder 214
- receptor for steroid hormones 214
Gastric acid secretion 1 distension 220
- effect of gastrointestinal hormones 220 emptying 89, 137 (A)
- nausea 89
histamine, role in acid secretion 1 juice 27 lesions 1
- role of histamine 1 mucosal damage 97 mucus 97
- stasis syndrome, treatment with 5-HT3 antagonist 89 gastrin 65, 114, 220
Glucose 35
- metabolic capacity 168(A) Glycoprotein tumor markers 128(A) Growth 175(A)
- factor(s) 180(A)
- receptors 175(A)
- response 139(A) GTP 183(A) I25I-GRP 142(A) Guargums 205 Guinea pigs 127(A)
- Hamster 130(A) Healthy smokers 27 Heicobacter pylori 46
- cytotoxicity in vitro 46
Hepatocytes 176(A)
Heredity 174(A)
Heterotopic pancreas 152(A)
High pressure liquid chromatography 181(A)
Histamine 1
Histamine decarboxylase 1
Hong Kong criteria 142(A)
Hormones 155(A)
- Horseradish-peroxidase 186(A)
- Human pancreatic secretion 166(A)
- studies 61
Humans 144(A), 165(A)
Hydrogen peroxide, protection by prostaglandins 97
- gastric damage, protection by proton-pump
inhibition 97 Hydroxyrutosidea 156(A) 25-Hydroxyvitamin D 61 5-Hydroxytryptamine 89
Hypercalcemia 137(A) Hypercholecystokininemia 161(A) Hyperglucagonemia 156(A), 169(A)
Idiopathic portal hypertension 193
IL6 185(A)
- Heal inhibitory phase 153(A)
Imaging procedures 168(A)
Immunoactivation assay 182(A)
Immunohistochemical characteristics, normal
pancreas 152(A) Incretin 144(A), 165(A) Infected severe acute pancreatitis 185(A) Infection
173(A), 185(A) Inflammation 199
Inflammatory bowel disease, epidemiology and occupation 10 Inhibition of IP3 formation
163(A) Inositol-1,4,5-trisphosphate 163(A) Insulin 135(A), 168(A), 169(A), 184(A)
Insulinoma 133(A) Interstitial pancreatitis 150(A) Intestinal iron transfer 35 Intracellular
magnesium 154(A) Intraduodenal bile 165(A) Intrapancreatic inhibitory peptide 148(A)
Iron 35
- overload 142(A)
Subject Index

Iron-transfer capacity, intestinal distribution 35
Islet hormones 172 (A)
Jejunal absorption 55
Jejunoileum, autotransplantation 178 (A)
6-Keto prostaglandin F1 159 (A)
Lectins 179 (A)
LH-RH 151 (A)
Lipolytic preparation 162 (A)
Lipopolysaccharides 161 (A)
Liver transplantation 239
- - normalization of menstrual cycle 239
Longitudinal gradient 35
Long-term follow-up 133 (A)
Low-affinity CCK receptors 133 (A)
Loxiglumide 147 (A)
- receptor antagonistic potency 180 (A)
Lung abscess 72
cavities, coeliac disease 72
disease 72
Lysosomal autophagic vacuoles 186 (A)
Malnutrition-related diabetes mellitus 126 (A)
Man 138 (A)
Mast cells 1
Menstrual cycle, liver disease 239
Methionine 180 (A)
Mice 139 (A)
Microcirculation 160 (A)
Microvascular perfusion 150 (A)
Mitogen for AR4-2J cells 131 (A)
Modafinil 163 (A)
Motility 214
- influence of guar gum 205
246
mRNA levels 134 (A), 186 (A)
Mucin hypersecretion 171 (A)
Mucosal biopsies 199
Na-tauro-deoxycholate 171 (A)
Nafamostat mesilate 158 (A)
Nausea 89
Necrohaemorrhagic pancreatitis 126 (A)
Necrotizing pancreatitis 157 (A), 183 (A)
Negative feedback, CCK release 184 (A)
- - regulation 141 (A)
Neuropeptide pituitary adenylate cyclase activating
peptide 130 (A)
Neurotensin 151 (A)
Neutralization of acid 123 (A)
Nucleotide sequence 144 (A)
Nutritional disorders 174 (A)
Obstructive pancreatitis 126 (A)
Occupation 10
Occupational distribution of IBD 10
Oedematous pancreatitis 126 (A)
Oesophageal varices, treatment 193
Oleic acid 146(A)
Ondansetron 89
One compartment model 19
Oral rehydration therapy 55
Organ culture 46
Ornithine decarboxylase 173 (A)
Orocecal transit time 205
Oxygen radical scavengers 133 (A)
PAF, Crohn’s disease 199
antagonist 161 (A) Pain 158(A)
relief 167(A) Pancreas 155 (A)
regeneration 148 (A) Pancreas-specific protein 132(A), 165(A)
transplants 165(A) Pancreatestatin 148(A) Pancreatectomy 168 (A) Pancreatic abscesses 129 (A)
acini 180(A)
biopsy 149(A)
blood flow 151 (A)
calculi, dissolution with trimethadione 19
cancer 151 (A), 167 (A), 168 (A), 169 (A), 171 (A)
- cells 176(A)
colipase 186(A)
deficiency 132(A)
denervation 151 (A)
disease 160 (A)
duct 152(A)
ductal morphology and function 154 (A)
enzyme composition, nonparallel changes 164(A)
- content 135(A)
- secretion 184 (A)
excretion 19
exocrine proteins, synthesis 172(A)
extracts 158 (A)
function 147(A), 153(A), 162(A)
glutathione 156(A)
growth 168 (A)
insufficiency 131 (A), 162 (A)
juice 127(A), 173(A)
-, bacteriostatic activity 127
lesions 135 (A)
lipase 182(A)
microcirculation 150 (A)
necrosis, dynamism 145(A)
polypeptide 141 (A), 142(A), 220
pseudocysts 177(A)
response to exogenous stimulation 127(A)
secretion 137(A), 181 (A)
- bicarbonate 123(A)
- cephalic phase 170 (A)
- tissue 136 (A)
Pancreatico-biliary diversion 139 (A) Pancreatico-trophic effect, bombesin 134 (A)
Pancreatitis 129(A), 133(A), 151 (A), 161 (A), 173(A)
colocalisation 186(A)
infection 185(A) Papillary abnormalities 183 (A) Pathogenesis of diabetes 15 5 (A)
Pathomorphologic alterations 154 (A) Peptic ulcer 65
Percutaneous drainage 129 (A)
Permeability 180(A)
PG analogues 166 (A)
Phagocytosis 124(A)
L-Phenylalanine 171 (A)
Phospholipid metabolism 187(A)
Phosphorylation 131 (A)
Photodynamic therapy, acinar pancreatic cancer
126(A) Physiologic nutrient malabsorption, mechanisms
153(A)
Subject Index
247

Pigs 185(A)
Pirenzepine 233
- comparison with cimetidine 233
Pituitary adenylate cyclase activating peptides
172(A) Plasma amino acid 142 (A), 149 (A)
insulin 141 (A)
trypsin 81 Plasminogen activator 125(A)
- inhibitor 125(A) Platelet-activating factor 199 Polyamine biosynthesis 173 (A) Polyposis,
normal gastrin and EGF 228 Postprandial PP response 161(A)
Potent protease inhibitory property 158 (A)
Predictive factors 107
Pregnancy 239
Progesterone 214
Propranolol 193
Prostacyclin 185 (A)
Prostaglandin E2 162 (A)
- FF 27
Prostaglandins 97
- gastric juice and smoking 27
Protein kinase 187 (A)
sequencing 140(A) Proton pump inhibition 97 Putrescine 180(A)
transport 125 (A)
Pylorus-preserving pancreatectomy \(140\) (A) PYY \(141\) (A), \(146\) (A)

Rabbit(s) \(138\) (A)

mandibular gland \(124\) (A)

pancreatic juice \(148\) (A)

Rat(s) \(131\) (A), \(133\) (A), \(134\) (A), \(135\) (A), \(136\) (A), \(150\) (A), \(168\) (A), \(176\) (A), \(180\) (A), \(181\) (A), \(187\) (A)

pancreas \(124\) (A), \(131\) (A)

pancreatic acini \(125\) (A)

- juice \(148\) (A)
- phospholipase A2 \(143\) (A)

pancreatic phospholipase A2 \(143\) (A) Reactive oxygen species \(97\)

Receptors \(214\)

Regulatory peptides \(228\)

Rehydration solution, role of glucose concentration \(55\)

Reticuloendothelial system \(124\) (A)

Rice starch H2 breath test \(131\) (A)

Sandostatin \(168\) (A) Satiety \(220\)

Sclerotherapy \(193\)

Secretagogue-evoked stimulation \(154\) (A) Secretin administration \(139\) (A), \(153\) (A)

- release \(139\) (A), \(153\) (A)

Secretory granules \(186\) (A)

Selenium \(188\) (A)

Serine proteases \(129\) (A)

Serum tumor marker \(138\) (A)

Sham feeding \(178\) (A)

Shock \(173\) (A)

Sjögren’s syndrome, primary \(154\) (A)

Somatostatin \(140\) (A), \(173\) (A)

- analogue \(170\) (A)

Sonographic guidance \(129\) (A)

Steroid hormones, gallbladder motility \(214\)

Stomach, human \(114\)

Structure of islets and acini \(152\) (A)

β-Thalassaemia major \(142\) (A)

Thromboxane \(A2\) \(185\) (A)

- B2 \(27\), \(159\) (A)

Thyrotropin-releasing hormone \(141\) (A) Tissue ischemia \(150\) (A)

TNF-α \(124\) (A), \(176\) (A)

α-Tocopherol \(148\) (A)

Total parenteral nutrition \(155\) (A)

Toxic mediators \(157\) (A)

Transferrin \(35\)

Treatment \(107\)

Trimethadione \(19\)

- pancreatic excretion \(19\)

Tripotassium dicitrato bismuthate \(65\)

Trophic effect \(139\) (A)

Tropical enteropathy \(55\)

- -, glucose concentration in rehydration solution
variants 188(A)
TRP 178(A)
Trypsin in plasma, effect of bombesin 81
secretion 157 (A) Trypsinogen activation peptide 143 (A)
cDNA 144(A) Tryptic activity 140(A) Tumoral model 126(A) Tumor sections 142 (A)
Ulcerative colitis 10, 107
-', predictive factors 107
248
Subject Index

Ultrasonographic examination 179 (A) Ultrasonography 145 (A), 167 (A) Ultrasound 149(A)
-', accuracy 168 (A) – scanning 177 (A)
Viruses 155 (A)
Viscosity 205
-', digestive contents, effect on intestinal motor
function 205 Vitamin D 61

Vagotomy 114
-', gastrin release by GRP 114
Variceal bleeding, sclerotherapy vs. propranolol
193
Zymogen granule(s) 179 (A) – heterogeneity 182(A)